<DOC>
	<DOC>NCT00148590</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy and safety of memantine as add-on treatment for the prevention of negative symptomatology in patients with an acute exacerbation of schizophrenia. Primary outcome parameter are negative symptoms after 6 months</brief_summary>
	<brief_title>Memantine for the Prevention of Negative Symptomatology</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Memantine</mesh_term>
	<criteria>Diagnosis of schizophrenia (DSMIV) Age 18 to 40 Exacerbation of an acute schizophrenic episode (PANSS positive score &gt; 20) At least one previous schizophrenic episode Informed consent Subjects must be considered by the investigator to be compliant Subjects must have an educational level and a degree of understanding such that they can meaningfully communicate with the investigator Axis I disorder other than schizophrenia within 12 months, e.g. schizoaffective disorder Severe negative symptomatology (PANNS negative score &gt;20 points) Duration of schizophrenia &gt; 5 years Dependency on alcohol or addictive drugs within 6 months of the baseline evaluation Contraindication of risperidone Significant neurological, cardiovascular, hepatic, renal, metabolic, or other medical diseases or any clinically relevant abnormalities in laboratory tests Prior ECTtreatment, metal implantations Female subjects during pregnancy and breastfeeding Female subjects within childbearing years who were not using adequate birth control Patients who are judged by the investigator to be at serious suicide risk</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Memantine</keyword>
	<keyword>Negative syndrome</keyword>
	<keyword>Schizophrenia</keyword>
	<keyword>Cognitive impairment</keyword>
	<keyword>Glutamate</keyword>
</DOC>